Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10697901

New tools for malaria therapy.

W E Gutteridge
View original source ↗Export metadata ↓

Abstract

In the absence of vaccines, new chemotherapies are needed urgently to help in the prevention and control of malaria. A number of strategies are being followed world-wide in attempts to discover and develop them: (a) resurrecting 'forgotten' molecules; (b) developing new formulations of existing products; (c) finding ways to bypass known toxicological limitations of existing products; (d) looking for combinations of existing products; (e) discovering molecules which reverse the resistance phenotype; (f) identifying 'old' chemical entities (OCEs) for new, antimalarial, indications; (g) discovering new chemical entities (NCEs) directed towards already exploited biological targets; (h) discovering NCEs directed to novel biological targets. Examples of such strategies are given below, together with an indication of their advantages and limitations.

Explore related subjects

Drug DesignDrug Therapy, CombinationHumansMalariaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W E Gutteridge. 1999. New tools for malaria therapy.. https://pubmed.ncbi.nlm.nih.gov/10697901/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Drug Design↗